Christopher Rudd

Christopher Rudd is a highly accomplished individual with a deep interest in the molecular basis of immunity and immune-based diseases. His educational background includes a Doctor of Philosophy (PhD) in Cancer Immunology from UCL, a Bachelor of Science (BSc) in Biochemistry and Molecular Biology from McGill University, and a Doctor of Science (D.Sc.) in Immunology from University College London, U. of London. He also studied FRCPath Immunology at the Royal College of Pathologists and earned a Master of Arts (M.A.) from the University of Cambridge.

Christopher has held various significant roles in prestigious organizations. He is currently a Professeur titulaire at the Université de Montréal. He has previous consulting and collaborative experience with organizations like NEOMED Institute, MEDIMMUNE LIMITED, Oxford Immunotec, Bristows Law Firm, and more. Christopher has been involved in leadership positions such as Head of the Immunotherapy Committee at the International Union of Immunological Societies (IUIS) and Council Member representing the United Kingdom at IUIS, emphasizing his expertise and contributions to the field.

With a rich professional history, Christopher has served as a Scientific Consultant at AstraZeneca, Amgen, and Oxford Immunotec Ltd, demonstrating his versatile skills and knowledge in various medical and research settings. He has also been a Professor of Molecular Immunology at Cambridge University and a Professor of Haematology at Imperial College London, reflecting his academic achievements and contributions to education and research. Additionally, his experience as an Instructor/Assistant/Associate Professor at Harvard Medical School and as a Member of the Board of Tutors at Harvard College underscores his impact in academia.